Akebia Therapeutics (AKBA)
(Delayed Data from NSDQ)
$1.42 USD
+0.11 (8.40%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $1.42 0.00 (0.00%) 5:32 PM ET
3-Hold of 5 3
D Value B Growth B Momentum B VGM
Brokerage Reports
Akebia Therapeutics, Inc. [AKBA]
Reports for Purchase
Showing records 21 - 40 ( 81 total )
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
3Q Recap; FDRR Submitted to Dispute Vadadustat''s CRL; Formal Response Expected by Year-end 2022; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
2Q Recap; Vadadustat''s Potential in ARDS is Intriguing But Outlook in CKD Anemia Remains Uncertain; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Otsuka Vadadustat Agreements Terminated; Akebia Receives a One-Time $55M Settlement Fee; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Otsuka Terminates Both U.S. and International Vadadustat Licensing Agreements; Reduce PT to $1.25
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
1Q Recap: Restructuring Continues to Rationalize Cost Structure; Expect EU Approval in 2H22; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Akebia Implements Workforce Reduction to Conserve Cash
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Presentation at NKF Refutes Increased Risk of Vascular Access Thrombosis
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
FDA Issues CRL for Vadadustat on Marginal Safety Concerns; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
4Q Recap: Keeping Watch With Bated Breath As Vadadustat Approaches March 29 PDUFA Date; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Amended Deal Terms With Vifor Pharma Signal High Confidence in Vadadustat With PDUFA Just Five Weeks Away
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
3Q Recap; Focus Tightens on Likely FDA Approval and Successful Launch of Vadadustat; PT Back Up to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Partner Otsuka Files MAA for Vadadustat in Europe; March 29 PDUFA Remains Key Focus; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
No AdCom Currently Planned For Vadadustat Ahead of March 29, 2022 PDUFA; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
1Q21 Recap; Awaiting NDA Acceptance and PDUFA Date by End of Month; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Vadadustat NDA Submission For Both Dialysis and Non-Dialysis CKD Patients One Quarter Ahead of Schedule, Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
4Q20 Recap: NDA Filing by Mid-2Q21; Potential FDA Approval Now January 2022 at the Earliest
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
3Q20 Recap: Early 2021 Vadadustat NDA Submission Based on Pre-NDA Meeting Feedback; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
New PROTECT Data Analysis at ASN Raises More Questions Than It Answers; PT to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Akebia Therapeutics, Inc.
Industry: Medical - Drugs
Selloff Way Overdone; We See Near-Term Gains Leading Into ASN; PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E